| VB4-845: VICINIUM™
|
|
|
| Protein Expression & Purification |
Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E.coli using high cell density fermentation
|
2011 |
|
Drug Design Development & Therapy
A Phase I Study of an Intravesical Administered Immunotoxin Targeting EpCAM for the treatment of Non Muscle-Invasive Bladder Cancer in BCG Refractory and BCG Intolerant Patients |
2010 |
|
Cancer Biotherapy & Radiopharmaceuticals
Preclinical Assessment of an Anti-EpCAM Immunotoxin: Locoregional Delivery Provides a Safer Alternative to Systemic Administration |
2009 |
|
Preclinical Safety Evaluation of BioPharmaceuticals Chapter 29
Preclinical Safety Evaluation of Immunotoxins |
2008 |
|
Current Opinion of Molecular Therapy
VB4-845, a conjugated recombinant antibody and immunotoxin for head & neck and bladder cancer |
2008 |
|
Level of Expression of EpCAM and Response to Vicinium™ in Non Muscle-Invasive Transitional Cell Carcinoma of the Bladder
|
2010 |
|
Frequency and Level of Expression of EpCAM in Non Muscle-Invasive Transitional Cell Carcinoma of the Bladder |
2009 |
|
Treatment with Intravesical Vicinium™ Results in Durable Responses in Patients with Carcinoma in situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG) |
2009 |
|
A Phase I/II Study of Vicinium™ Given by Intravesical Administration in Patients with Superficial Transitional Cell Carcinoma of the Bladder: Phase I Final Results |
2007 |
|
| VB4-845: PROXINIUM™
|
|
|
Cancer Biotherapy & Radiopharmaceuticals Preclinical
Assessment of an Anti-EpCAM Immunotoxin: Locoregional Delivery Provides a Safer Alternative to Systemic Administration
|
2009 |
|
Preclinical Safety Evaluation of BioPharmaceuticals Chapter 29
Preclinical Safety Evaluation of Immunotoxins |
2008 |
|
Current Opinion of Molecular Therapy
VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer |
2008 |
|
Journal of Drug Design, Development and Therapy
A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck |
2008 |
|
Medical Oncology
A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck |
2008 |
|
Clinical Cancer Research
A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity |
2003 |
|
Treatment of Squamous Cell Carcinoma of the Head and Neck with Proxinium™: Preliminary Results
|
2008 |
|
Evaluation of the immunotoxin, Proxinium™ in combination with chemotherapy and radiotherapy
|
2007 |
|
A Phase I Study of VB4-845 in Patients with Advanced, Recurrent Head and Neck Cancer on a Weekly Dosing Scheme
|
2005 |
|
| VB6-845
|
|
|
Journal of Immunotherapy
Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin
|
2009 |
|
A Phase I Study of VB6-845, an Anti-EpCAM Fusion Protein Targeting Advanced Solid Tumours of Epithelial Origin: Preliminary Results |
2008 |
|
Intracellular trafficking of VB6-845, an immunocytotoxin containing a de-immunized variant of bouganin |
2008 |
|
Enhancement of expression of a Fab format of a cytotoxic therapeutic protein produced in an Escherichia coli expression system; scale up of process from 15 L development scale to 1200 L production scale for phase I trials |
2007 |
|
Complete regression of ovarian cancer xenografts following treatment with the recombinant immunocytotoxic protein, VB6-845 |
2006 |
|
A preclinical profile of VB6-845: a recombinant immunotoxin for targeting ovarian cancer |
2006 |
|
Recombinant Engineering of an EpCAM-specific Fab antibody (VB6-845) with de-immunized bouganin |
2005 |
|
Functional and biological characterization of VB6-845, a recombinant EpCAM-specific Fab antibody genetically-linked with de-immunized Bouganin (De-Bouganin) |
2005 |
|
| IDAP |
|
|
Journal of Biomolecular Screening |
Fusogenics: A recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments
|
2010 |
|
| Fusogenics™: A novel approach to antibody affinity maturation |
2008 |
|
| A functional high-throughput assay for selection and isolation of tumor-specific recombinant antibodies |
2007 |
|
| ANTIGENS |
|
|
Biochemical and Biophysical Research Communications
A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab™ PF-2D in tandem with mass spectrometry |
2006 |
|
| VB1-008: Identification of a fully-human antibody specific for CD44E and CD44-isoform-3 |
2006 |
|
| Identification of membrane-associated cancer-specific drug targets using the ProteomeLab™ PF-2D, in tandem with mass spectrometry |
2005 |
|
| DE-BOUGANIN
|
|
|
Journal of Immunotherapy
Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin
|
2009 |
|
Preclinical Safety Evaluation of BioPharmaceuticals
Chapter 29
Preclinical Safety Evaluation of Immunotoxins |
2008 |
|
Complete regression of ovarian cancer xenografts following treatment with the recombinant immunocytotoxic protein, VB6-845 |
2006 |
|
Recombinant engineering of an Ep-CAM-specific Fab antibody (VB6-845) with de-immunized bouganin |
2005 |
|
De-Immunized Bouganin: An innovative, antibody-directed, cytotoxic payload for a safer and more efficacious treatment of cancer |
2005 |
|
Epitope-Depleted Bouganin: An innovative, antibody-directed, cytotoxic payload for a safer and more efficacious treatment of cancer
|
2005 |
|
 |
